World’s first Intranasal vaccine iNCOVACC gets DCGI approval for Covid booster doses

Tags: Science and Technology

Bharat Biotech International Limited (BBIL) has announced on 29 November that the iNCOVACC vaccine has become the world's first intra-nasal vaccine to receive primary series and heterologous booster approval.

Important facts

• Bharat Biotech International Limited (BBIL) is a global leader in vaccine innovation and developer of vaccines for infectious diseases.

• Now iNCOVACC (BBV154) can be used in India under restricted use in emergency from the Central Drugs Standard Control Organization (CDSCO) for heterologous booster dose for age above 18 years.

• This nasal vaccine is the second approved COVID-19 vaccine in India after Biological E's Corbevax, which can be used as a mix-and-match booster shot.

• iNCOVACC is a recombinant replication deficient adenovirus vectored vaccine with a pre-fusion stabilized SARS-CoV-2 spike protein.

• iNCOVACC has been specially formulated to allow intranasal delivery via nasal drops.